Table 2.
Comparison of RCTs accessing RCHD with trials evaluated by the HRA in 2015
| RCTs accessing RCHD (n = 160) |
HRA in 2015a (n = 963b) |
|
|---|---|---|
| Recruitment setting | ||
| Primary care | 41 (26%) | 48 (5%) |
| Secondary care | 119 (74%) | 846 (95%) |
| Unclear/missing | 0 | 69 |
| Therapeutic area | ||
| Cancer | 47 (29%) | 168 (17%) |
| Cardiovascular and stroke | 46 (29%) | 121 (13%) |
| Pregnancy and childbirth | 9 (6%) | 30 (3%) |
| Infection | 8 (5%) | 55 (6%) |
| Inflammatory disorder | 5 (3%) | 72 (7%) |
| Drug trial | 76 (48%) | 515 (53%) |
| Randomisation | ||
| Individual | 136 (85%) | 934 (97%) |
| Cluster trial | 24 (15%) | 29 (3%) |
| Feasibility/pilot | 17 (11%) | 177 (18%) |
| Sample size (median, range) | 1590 (41–6,000,000) | 275 (6–30,000) |
| Unclear/missing | 0 | 440 |
| Recruitment location | ||
| UK only | 125 (78%) | 450 (50%) |
| International trials | 32 (20%) | 443 (50%) |
| Unclear/missing | 0 | 70 |
This table only includes data fields that were comparable between the two sources. Sample size targets in the UK Health Research Authority (HRA) cohort are limited to those not described as phase I/II trials. Data obtained from Clark et al. [11] (2018), including unpublished supplementary appendices [1]. Abbreviations: RCHD routinely collected health data, RCT randomised controlled trial
aClark et al. [11].
bFor recruitment setting and location, the unclear/missing values were omitted from the percentage calculation.